Real-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)

Source: ADA Diabetes June 2021

Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.

Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment

*PPPM = per patient per month

Advancing Glycemic Management in People with Diabetes

Source: The IQIVA Institute

About the report: The incorporation of time in range (TIR) metrics alongside HbA1c is expected to enhance the way in which diabetes is managed in the future, and subsequently, reduce the overall societal and economic burden. To assess the value of improving TIR from its current state to the minimum consensus target of 70% and 80% TIR, the IQVIA Core Diabetes Model was used to estimate cost reductions in complications and costs associated with improving TIR. Using this model, improvements in TIR were estimated to reduce the risk of developing diabetes-related complications resulting in a conservative reduction of $2.1-7 billion in costs over a 10-year period, based on the relationship between TIR and HbA1c. The addition of incrementally reducing hypoglycemic events in people with Type 1 Diabetes by 40% and improving TIR to 80% generated a total 10-year cost reduction of $6.7-9.7 billion. This reduction in costs represents a conservative estimate.

10-Year Cost Reduction  by Improving TIR in People with T1 and T2 Diabetes to 70% and 80% TIR (US$Bn)

Free On-demand Webinar: A Movement in Diabetes: Using Time-in-Range

Source: Applied Clinical Trials

Key Takeaway: This webinar presents the first estimation of reduction in complications and costs associated with improving time-in-range per research found in the Advancing Glycemic Management in People with Diabetes report. You will hear directly from an advocate for people with diabetes about the Time-in-Range movement and gain an understanding about what’s to come in the realm of diabetes care management.

A Cost Offset Analysis (COA) Comparing Real-Time Continuous Glucose Monitoring (RT-CGM) With Intermittent Scanning Continuous Glucose Monitoring (IS-CGM) in Type 1 Diabetes (T1D) Subjects With Impaired Hypoglycemia Awareness in Eight Countries

Source: Value in Health. 2019: Volume 22 S572. doi: 10.1016/j.jval.2019.09

Key Takeaway: A recent RCT comparing an rt-CGM and is-CGM device demonstrated differences in %TIR over several glucose ranges allowing for projection of potential clinical outcomes. A COA was performed comparing these clinical cost offsets for rt-CGM and is-CGM in people with T1D (n=2,000) and impaired awareness of hypoglycemia (IAH; ~30% of people with T1D), applied to eight countries each over a one-year period. The demonstrated differences in %TIR spent at low, optimal, and high glucose ranges are likely to translate into significant clinical and economic benefits for rt-CGM compared with is-CGM.

Cost Offset Analysis (COA) Comparing Real-Time Continuous Glucose Monitoring (RT-CGM) With Self-Monitoring of Blood Glucose (SMBG) in People With Type 1 Diabetes in Eight Countries

Source: Advanced Technologies & Treatments in Diabetes

Key Takeaway: A cost offset analysis (COA) was performed comparing potential clinical cost offsets for reduced HbA1c, severe hypoglycemia, and diabetic ketoacidosis using a rt-CGM system compared with SMBG alone in people with Type 1 Diabetes (T1D) and uncontrolled glycemia, in eight countries (n=5,000 per country), over a one-year time period. This modelling study demonstrates significant potential clinical and economic benefits for rt-CGM compared with SMBG in people with T1D.